Skip to main content
SpringerLink
Log in

The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year’s growth response in GH-deficient children

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Serum GH levels were measured in 9 prepubertal children with growth hormone (GH) deficiency using an immunofluorometric assay (IFMA) and a Nb2 cell bioassay, prior to and 2, 4, 6 and 12 hours after the first hGH subcutaneous injection (sc) (0.1 IU/Kg). After this first acute phase, hGH treatment was continued regularly at a dose of 0.1 IU/kg per day at bedtime. The acute pharmacokinetic profile was similar in the patients irrespectively of the assay used: serum GH usually starts to rise after 2 hours, peaks by 4 or 6 hours and drops back to near baseline levels 12 hours after sc GH administration. A great variation in the amplitude of peak levels was observed among the patients. The assays significantly (p<0.0001) correlate with each other in all subjects. An increase in serum GH values as evaluated by the Nb2 bioassay was observed in most children after sc GH injection, suggesting that the administered hormone preserves its biological activity. The individual variations in GH bioactivity in our GH-deficient children could be due to different mechanisms of the drug’s degradation at the site of injection or in circulation. Pre-treatment height velocity calculated as standard deviation scores (SDS) significantly increased (p<0.001) from -2.77±0.42 to 1.22±0.87 SDS after a 12-month period of GH treatment in 8 patients who had already completed the first year of therapy, although it varied considerably among subjects. A higher serum GH peak value evaluated by both assays corresponded to a higher growth response during the 1st year, but not in the 2nd year of GH therapy. In conclusion, the degree of GH bioactivity released into circulation after sc GH injection may vary considerably among GHD patients and correlates with the growth response observed during the 1st year of GH therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Guidelines for the use of growth hormone in children with short stature. J. Pediatr. 1995, 127: 857–867.

    Article  Google Scholar 

  2. Fraiser S.D., Costin G., Lippe B.M., Aceto T., Bunger P.F. A dose-response curve for human growth hormone. J. Clin. Endocrinol. Metab. 1981, 53: 1213–1217.

    Article  Google Scholar 

  3. Frasier S.D. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr. Rev. 1983, 4: 155–170.

    Article  Google Scholar 

  4. Preece M.A., Tanner J.M., Whitehouse R.H., Cameron N. Dose dependence of growth response to human growth hormone in growth hormone deficiency. J. Clin. Endocrinol. Metab. 1976, 42: 477–483.

    Article  CAS  PubMed  Google Scholar 

  5. Ranke M., Weber B., Bierich J.R. Long-term response to human growth hormone in 36 children with idiopathic growth hormone deficiency. Eur. J. Pediatr. 1979, 132: 221–238.

    Article  CAS  PubMed  Google Scholar 

  6. Job J.C., Chaussain J.L., Garnier P., Rolland A., Joab N. Dose-response relationship in the treatment of hypopituitary children with human growth hormone: a retrospective survey. Acta Paediatr. Scand. 1987, 337(Suppl.): 93–105.

    Article  CAS  Google Scholar 

  7. Kastrup K.W., Christiansen S.J., Andersen K.J., Onskov H. Increased growth rate following transfer to daily subcutaneous administration from three weekly intramuscular injections of hGH in growth hormone deficient children. Acta Endocrinol. 1983, 104: 148–152.

    CAS  PubMed  Google Scholar 

  8. Greulich W., Pyle S.I. Radiographic Atlas of Skeletal Development of the Hand and Wrist, ed. 2. Stanford University Press, Palo Alto, 1959.

    Google Scholar 

  9. Albertsson-Wikland K., Jansson C., Rosberg S., Novamo A. Time-resolved immunofluorometric assay of human growth hormone. Clin. Chem. 1993, 39: 1620–1625.

    CAS  PubMed  Google Scholar 

  10. Rott A.W., Duckett G.E., Geiszler J.E., Hu C.S., Bercu B.B. Evaluation of the clinical utility of the ultrasensitive immunofluorometric assay for growth hormone (GH) and of the cortisol secretory pattern in prediction of the linear growth response to treatment with GH. J. Pediatr. Endocrinol. Metab. 1997, 13: 3–10.

    Google Scholar 

  11. Tanaka T., Shiu R.P.C., Gout P.W., Beer C.T., Noble R.L., Friesen H.G. A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum. J. Clin. Endocrinol. Metab. 1980, 51: 1058–1063.

    Article  CAS  PubMed  Google Scholar 

  12. Walker A., Croze F., Friesen H.G. A serum-free medium for culturing lactogen dependent and autonomous Nb2 node lymphoma cells. Endocrinology 1987, 120: 2389–2397.

    Article  CAS  PubMed  Google Scholar 

  13. Bozzola M., Zecca M., Locatelli F., Radetti R., Pagani S., Autelli M., Tatò L., Chatelain P. Evaluation of growth hormone bioactivity using the Nb2 cell bioassay in children with growth disorders. J. Endocrinol. Invest. 1998, 21: 765–770.

    CAS  PubMed  Google Scholar 

  14. Hintz R.L., Rosenfeld R.G., Wilson D.M., Bennet A., Finno J., McClellan B., Swify R. Biosynthetic methionyl human growth hormone is biologically active in adult man. Lancet 1982, i: 276–279.

    Google Scholar 

  15. Takano K., Hizuka N., Shizume K., Asakawa K., Kogawa M. Short-term study of biosynthesised hGH in man. Endocrinol. Jpn. 1983, 30: 79–84.

    Article  CAS  PubMed  Google Scholar 

  16. Takano K., Shizume K. Current clinical trials with authentic recombinant human growth hormone in Japan. Acta Paediatr. Scand. 1986, 325(Suppl.): 93–97.

    Article  CAS  Google Scholar 

  17. Wilton P., Sietnieks A. An open-labelled study of the safety acute metabolic activity and pharmacokinetic profile of a short-term course of recombinant human growth hormone in healthy volunteers. Clin. Endocrinol. (Oxf.) 1987, 26: 125–128.

    Article  CAS  Google Scholar 

  18. Usala A.L., Blumer J.L. Pharmacology of new hormonal therapies in the treatment of paediatric endocrine disorders. Pediatr. Clin. North Am. 1989, 36: 1157–1182.

    CAS  Google Scholar 

  19. Moore J.A., Rudman C.G., McLachlan N.J., Fuller G.B., Burnett B., Frane J.W. Equivalent potency and pharmacokinetics of recombinant human growth hormones with or without an N-terminal methionine. Endocrinology 1988, 122: 2920–2926.

    Article  CAS  PubMed  Google Scholar 

  20. Levin P., Chalew S., Martin L., Kowarski A. Comparison of assays for growth hormone using monoclonal or polyclonal antibodies for diagnosis of growth disorders. J. Lab. Clin. Med. 1987, 109: 85–88.

    CAS  PubMed  Google Scholar 

  21. Woodhead S., Turner G. Accuracy of growth hormone measurements. Horm. Res. 1991, 36(Suppl.): 17–20.

    Article  PubMed  Google Scholar 

  22. Albertsson-Wikland K. The effect of human growth hormone injection frequency on linear growth rates. Acta Paediatr. Scand. 1987, 337(Suppl.): 110–116.

    Article  CAS  Google Scholar 

  23. Jorgensen J.O.L., Moller N., Lauritzen T., Christiansen J.S. The absorption kinetics of subcutaneously administered growth hormone: influence of injection volume. J. Pediatr. Endocrinol. 1989, 3: 213–215.

    Google Scholar 

  24. Christiansen J.S., Orskov H., Binder C., Kastrup K.W. Imitation of normal plasma growth hormone profile by subcutaneous administration of human growth hormone to growth hormone deficient children. Acta Endocrinol. (Copenh.) 1983, 102: 6–10.

    CAS  Google Scholar 

  25. Houdijik E.C.A.M., Herdes E., Delemarre-Van de Waal H.A. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta Paediatr. 1997, 86: 1301–1307.

    Article  Google Scholar 

  26. Baumann G. Heterogeneity of growth hormone. In: Bercu B.B., (ed.) Basic and clinical aspects of growth hormone. Plenum Press, New York, 1988, pp. 13–31.

    Chapter  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Scienze Pediatriche, Università di Pavia, IRCCS Policlinico San Matteo, Piazzale C. Golgi 2, 27100, Pavia, Italy

    M. Bozzola M.D., S. Pagani, M. Draghi & G. Rondini

  2. Dipartimento di Pediatria, Ospedale Regionale, Bolzano, Italy

    G. Radetti

  3. Divisione di Endocrinologia, Dipartimento di Medicina Interna, Università di Torino, Ospedale Molinette, Torino, Italy

    G. Aimaretti

Authors
  1. M. Bozzola M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Radetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Pagani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Draghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Aimaretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Rondini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bozzola M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bozzola, M., Radetti, G., Pagani, S. et al. The level of bioavailable growth hormone (GH) after the first GH injection predicts the first year’s growth response in GH-deficient children. J Endocrinol Invest 22, 790–795 (1999). https://doi.org/10.1007/BF03343645

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343645

Key-words

Search

Navigation